Gene-Disorder Association · Article
Gene
CDKN2A Cyclin Dependent Kinase Inhibitor 2A
×
First reported
1995
Supporting publications
52
Manually curated Approved treatment annotated
Association Review
In brief The association between CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) and Lung Non-Small Cell Carcinoma is reported, with clinical genetic testing available.
Sources
1
Clinical variants
0
Symptoms
0
Compounds
6
Trials
1,241 of 7,342 via CDKN2A compounds
Publications
52
Contents
01
At a glance
Association overview A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access 02
Provenance
Evidence and sources 1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access 2 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access 04
Lung Non-Small Cell Carcinoma
The disorder 6 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access 05
Mechanism overlap
Shared mechanisms 1 shared pathway
Biological pathways and phenotype concepts shared by the gene and the disorder, with supporting publications.
Request access 06
Interventions
Therapeutics 6 compounds & drugs
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access 07
Human studies
Clinical trials 7,342 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access 52 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access 09
Provenance
References & sources 17 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access 
